VIDEO: Ivosidenib or enasidenib plus chemotherapy shows promise in IDH-mutated AML
Ivosidenib or enasidenib in combination with chemotherapy showed promising safety and efficacy profiles for newly diagnosed IDH-mutated acute myeloid leukemia, according to a phase 1 trial presented at ASH Annual Meeting and Exposition.
Richard M. Stone, MD, of Dana-Farber Cancer Institute, discussed the “impressive” response rates and OS. With a median follow-up of almost 2 years, the long-term OS was about 65% to 70% in both groups, he told Healio in a video interview.
“The big question for clinicians is whether a patient who walks in the door today with IDH1 or IDH-mutant AML should have ivosidenib or enasidenib attached to their chemotherapy,” Stone said. “My conservative answer to that is no. We have to wait for the large, randomized trial... comparing 3 + 7 chemo to 3+7 plus the respective IDH inhibitor.”
Targeted therapy could be a “very important therapeutic advance” in AML, but Stone noted that these bigger trials are harder to do because these mutations represent small subsets of AML.
“I personally think it will be better than 3 + 7 alone, but we need to prove that,” he said.
Collapse
Stein EM, et al. Abstract 1276. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021; Atlanta